๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation

โœ Scribed by Ying K Tam; Hans-G Klingemann

Book ID
117816128
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
201 KB
Volume
5
Category
Article
ISSN
1083-8791

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Rituximab with interleukin-2 after autol
Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission
โœ Ozsahin, Hulya ;Fluss, Jo๏ฟฝl ;Mc Lin, Valerie ;Wacker, Pierre ;Miralbell, Raymond ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 35 KB

To the Editor: Relapse is still a problem for leukemias, particularly in the autologous bone marrow transplantation (ABMT) setting. Moreover, the CD20 positive phenotype, deยฎned as >20% expression, may be associated with a worse outcome [1]. Therefore, our experience with such a patient in whom we a

High-dose systemic interleukin-2 therapy
High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: Pilot study
โœ Pardo, N.; Martรญ, F.; Fraga, G.; Illa, J.; Badell, I.; Peirรณ, M.; Bertran, E.; G ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 610 KB

Despite intensified chemotherapy protocols, including autologous bone marrow transplantation (ABMT), stage IV neuroblastoma has a poor prognosis, and modern therapeutic trends are aimed at the eradication of minimal residual disease, which is thought to be the main factor leading to relapse. In this